Yoshii Toyofumi, Iwai Masaru, Li Zhen, Chen Rui, Ide Ayumi, Fukunaga Shiori, Oshita Akira, Mogi Masaki, Higaki Jitsuo, Horiuchi Masatsugu
Second Department of Internal Medicine, Ehime University School of Medicine, hitsukawa, Tohon, Japan.
Hypertens Res. 2006 Jun;29(6):457-66. doi: 10.1291/hypres.29.457.
We examined whether amlodipine, an L-type calcium channel blocker (CCB), has an inhibitory effect on oxidative stress and inflammatory response, and thereby atherosclerosis, in apolipoprotein E-deficient (ApoEKO) mice. Adult male ApoEKO mice (6 weeks of age) were fed a high-cholesterol diet (HCD) for 8 or 10 weeks with or without oral administration of amlodipine (3 mg/kg/day) for 10 weeks or for only the last 2 weeks of the HCD. After HCD feeding, atherosclerotic lesion formation, in situ superoxide production and nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase activity were evaluated in the proximal aorta. The expressions of NADPH oxidase subunits (p47(phox) and rac-1), monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) were determined with immunohistochemistry and quantitative real-time reverse-transcription polymerase chain reaction. After 8 to 10 weeks of HCD administration to ApoEKO mice, marked atherosclerotic lesion formation was observed in the proximal aorta. In the atherosclerotic lesion, superoxide production, the expression of NADPH oxidase subunits, and NADPH oxidase activity were enhanced, and the expressions of MCP-1, ICAM-1, and VCAM-1 were increased. These changes were suppressed in mice that were treated with amlodipine for 10 weeks concomitant with HCD administration, with no significant change in blood pressure and plasma cholesterol level. We also observed that treatment with amlodipine for only the last 2 weeks regressed the atherosclerotic lesions with a decrease in oxidative stress and vascular inflammation. Inhibition of the atherosclerotic lesion area and lipid area in the proximal aorta by amlodipine was correlated with its inhibitory actions on oxidative stress, inflammation and the production of adhesive molecules. These results suggest that amlodipine not only inhibits atherosclerotic lesion formation, but also regresses atherosclerosis, and that these effects are at least partly due to inhibition of oxidative stress and inflammatory response.
我们研究了L型钙通道阻滞剂(CCB)氨氯地平是否对载脂蛋白E缺陷(ApoEKO)小鼠的氧化应激、炎症反应以及动脉粥样硬化具有抑制作用。成年雄性ApoEKO小鼠(6周龄)喂食高胆固醇饮食(HCD)8或10周,期间有或没有口服氨氯地平(3毫克/千克/天)10周,或者仅在HCD喂养的最后2周口服氨氯地平。HCD喂养后,评估近端主动脉的动脉粥样硬化病变形成、原位超氧化物生成以及烟酰胺腺嘌呤二核苷酸磷酸(NADPH)氧化酶活性。采用免疫组织化学和定量实时逆转录聚合酶链反应测定NADPH氧化酶亚基(p47(phox)和rac-1)、单核细胞趋化蛋白-1(MCP-1)、细胞间黏附分子-1(ICAM-1)和血管细胞黏附分子-1(VCAM-1)的表达。给ApoEKO小鼠喂食HCD 8至10周后,在近端主动脉观察到明显的动脉粥样硬化病变形成。在动脉粥样硬化病变中,超氧化物生成、NADPH氧化酶亚基的表达以及NADPH氧化酶活性增强,MCP-1、ICAM-1和VCAM-1的表达增加。在HCD给药期间同时用氨氯地平治疗10周的小鼠中,这些变化受到抑制,血压和血浆胆固醇水平无显著变化。我们还观察到,仅在最后2周用氨氯地平治疗可使动脉粥样硬化病变消退,氧化应激和血管炎症减轻。氨氯地平对近端主动脉动脉粥样硬化病变面积和脂质面积的抑制作用与其对氧化应激、炎症以及黏附分子产生的抑制作用相关。这些结果表明,氨氯地平不仅抑制动脉粥样硬化病变形成,还能使动脉粥样硬化消退,且这些作用至少部分归因于对氧化应激和炎症反应的抑制。